GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
Links shared publicly online about this topic.
- 960total visits
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
gsk.com —
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top line results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).
View full resource at gsk.com
Tags: Leukemia, Chronic Lymphocytic Leukemia, GlaxoSmithKline
Most Recently Shared on August 9, 2010 at 9:10 pm By:
GSK & Genmab - resultsof pivotal trial Arzerra (ofatumumab) in fludarabine & alemtuzumab refr chron lymphocytic leukemia http://ow.ly/2ncoe
Advertisement
